NCT01791231View on ClinicalTrials.gov

A Study to Investigate the Absorption, Metabolism, and Excretion of Canagliflozin (JNJ-28431754) in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

September 30, 2007

Study Completion Date

October 31, 2007

Conditions

Healthy

Interventions

DRUG

Radiolabelled 14C-canagliflozin (14C-JNJ-28431754)

A single oral dose of 196 mg radiolabeled 14C-canagliflozin (14C-JNJ-28431754) liquid suspension containing approximately 40 microcurie (1480 kBq) of 14C radioactivity will be administered on Day 1.

Trial Locations (1)

Unknown

Merksem

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT01791231 - A Study to Investigate the Absorption, Metabolism, and Excretion of Canagliflozin (JNJ-28431754) in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter